The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS : challenges and opportunities : summary of a joint workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences
Olson, Steve, 1956-
The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS : challenges and opportunities : summary of a joint workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences [E-Book] - 1 online resource (1 PDF file (xxi, 195 pages)) : illustrations
Title from PDF title page.
Includes bibliographical references.
The challenges and opportunities for the BRICS countries to lead -- Catching up with the microbe -- Drug-resistant TB in China -- Experiences with MDR TB in other countries -- Drug-resistant tuberculosis in pediatric populations -- Global perspectives on transmission and infection control -- Rapid diagnostic technologies : status and limitations -- Addressing diagnosis and treatment across the spectrum of drug resistance -- Developing and strengthening the drug supply chain for drug-resistant TB -- Embracing a new vision for research -- What will be required to achive zero deaths from TB? -- Creating an evidence-based blueprint for action.
Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.
9780309285964 0309285968 9780309285971 0309285976
2014451576
101633144 DNLM
Multidrug-resistant tuberculosis--Congresses.
Multidrug-resistant tuberculosis--Prevention--Congresses.
Tuberculosis--Congresses.
Drug resistance--Congresses.
Multidrug-resistant tuberculosis.
Antitubercular agents.
World health.
International cooperation.
Tuberculosis, Multidrug-Resistant
Antitubercular Agents
Global Health
International Cooperation
China
2014 I-005 WF 200
The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS : challenges and opportunities : summary of a joint workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences [E-Book] - 1 online resource (1 PDF file (xxi, 195 pages)) : illustrations
Title from PDF title page.
Includes bibliographical references.
The challenges and opportunities for the BRICS countries to lead -- Catching up with the microbe -- Drug-resistant TB in China -- Experiences with MDR TB in other countries -- Drug-resistant tuberculosis in pediatric populations -- Global perspectives on transmission and infection control -- Rapid diagnostic technologies : status and limitations -- Addressing diagnosis and treatment across the spectrum of drug resistance -- Developing and strengthening the drug supply chain for drug-resistant TB -- Embracing a new vision for research -- What will be required to achive zero deaths from TB? -- Creating an evidence-based blueprint for action.
Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.
9780309285964 0309285968 9780309285971 0309285976
2014451576
101633144 DNLM
Multidrug-resistant tuberculosis--Congresses.
Multidrug-resistant tuberculosis--Prevention--Congresses.
Tuberculosis--Congresses.
Drug resistance--Congresses.
Multidrug-resistant tuberculosis.
Antitubercular agents.
World health.
International cooperation.
Tuberculosis, Multidrug-Resistant
Antitubercular Agents
Global Health
International Cooperation
China
2014 I-005 WF 200